SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
NCT07489703
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
SHR-A1811 plus AK112
Sponsor
Sun Yat-sen University